Columns | Clinical Trial Insights

Self-determined eligibility and the influence of clinical care challenge this flawed figure.

The struggle to translate promising movements in R&D.

AI presents rare opportunity to assess the scope of this longtime challenge.

Study holds new benchmarks and improvement opportunities.

Record numbers point to new R&D operating environment, driven by a changing community of sponsors.

It’s time to establish standard practices to return clinical trial results summaries to patients.

New study reveals that inconsistent, tactical, and reactive outsourcing practices predominate.

Reexamining traditional cycle-time reduction strategies is critical for sponsors, CROs, and sites.

Amid industry feedback that the growing volume and diversity of eClinical data collected for studies is taxing cycle times, two studies highlight the need to optimize protocol design and executional complexity to overcome these data management burdens.

Study examines the growing integration of real-world data and evidence and the remaining roadblocks to adoption.    

Recent study, and others in literature, inform misconceptions around physician and nurse involvement in clinical trials. 

Traditional and new players are seeing growth and opportunity as the integration of clinical research and healthcare intensifies.    

The nascent and fragmented global community of investigators is showing signs of scaling and maturing.

Examining the evolution of protocol design and collaboration executing strategies.

Recent studies may help break down barriers to implementing patient-centric initiatives.

New study finds that the long-strained relationship between sites and institutional review boards may finally be improving.

New study finds that most biopharma companies are now using a standard set of key performance indicators.

Research reveals a need for sponsors to be much more consistent, disciplined and focused in their CRO usage.

Work burden and performance hurt by technology incompatibility.

Study provides real metrics on the trial-scope affects of protocol changes-shedding fresh light on the importance of adopting new strategies to reduce select amendments.

Despite wealth of data collected, many inefficiencies exist in the site-sponsor transfer of insights from clinical trials.

Study uncovers subtle distinctions in attitudes and perceptions among the two groups.

Survey provides new benchmarks on e-solutions adoption, but actual impact data remains elusive.

While still early days, key metrics can be collected in three broad areas

Study takes rare look at the financial and resource burden for sites in managing regulatory compliance.

Study shows that industry contributions to R&D go well beyond the applied area of clinical testing.

Research shows that the potential of integrated alliances remains elusive in the near term.

Unique feedback from patient survey could help inform future clinical supply design and implementation.

Science exhibit will give children and young adults a rare look inside clinical trial patient experience.

Half of all drugs in clinical testing are interrupted by in-licensing, co-development, joint venture and M&A arrangements – and they are taking significantly more time to develop.